Although the term “smoldering myeloma” was coined in the late 1970s, 1 much debate still surrounds its definition. According to Natalie S. Callander, MD, Professor of Medicine, University of Wisconsin Carbone Cancer Center, patients defined as
Presenter : Natalie S. Callander
Jacalyn Rosenblatt and David Avigan
multiple myeloma List the immunotherapeutic strategies currently being evaluated in clinical trials for treatment of multiple myeloma Allogeneic Transplantation: Proof of Principle for Immunotherapy Outcomes for patients with multiple
Kenneth C. Anderson
“I believe not only that multiple myeloma will be a chronic illness, but also that we will see sustained complete responses in a significant fraction of patients,” predicted Kenneth C. Anderson, MD, as he described the emerging landscape in
Alessandra Larocca and Antonio Palumbo
Multiple myeloma (MM) is the second most common hematologic malignancy. It accounts for 1% of all cancers and 13% of hematologic neoplasms. The median age at diagnosis is 70 years, with 37% of patients younger than 65 years, 26% aged 65 to 74
Jorge J. Castillo
Numerous advances have recently been made in the treatment of relapsed/refractory (R/R) multiple myeloma (MM): novel immunomodulators, proteasome inhibitors, monoclonal antibodies, histone deacetylase inhibitors, and nuclear export inhibitors have
Shaji K. Kumar, Natalie S. Callander, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jorge Castillo, Jason C. Chandler, Caitlin Costello, Matthew Faiman, Henry C. Fung, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Yubin Kang, Adetola Kassim, Michaela Liedtke, Ehsan Malek, Thomas Martin, Vishala T. Neppalli, James Omel, Noopur Raje, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Donna Weber, Joachim Yahalom, Rashmi Kumar and Dorothy A. Shead
for Multiple Myeloma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Multiple Myeloma NCCN Guidelines Insights : Multiple Myeloma, Version 3.2018 Version 3.2018 © National Comprehensive
Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Frederic J. Reu, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead and Rashmi Kumar
activity, participants will be able to: Integrate into professional practice the updates to NCCN Guidelines for Multiple Myeloma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Multiple Myeloma
Kenneth C. Anderson
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Multiple Myeloma contain 2 important updates that should translate into more effective treatment with available agents. However, what is particularly exciting to Kenneth C
Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Cristina Gasparetto, Carol Ann Huff, Madan Jagasia, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Guido Tricot, Julie M. Vose, Donna Weber, Joachim Yahalom and Furhan Yunus
the express written permission of the NCCN © 2009. Disclosures for the NCCN Multiple Myeloma Guidelines Panel At the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from industry
Luciano J. Costa and Saad Z. Usmani
Defining High-Risk Multiple Myeloma Multiple myeloma (MM) is biologically heterogeneous, leading to wide variability in response to therapy and survival. The definitions of subsets of patients with high risk have evolved with diagnostic and
